← All trials
NCT06490328
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 30, 2024
- Primary completion
- May 20, 2025
- Completion date
- May 20, 2025
- First posted
- Jul 8, 2024
- Last posted
- Jul 8, 2024
- Enrollment
- 154
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Dongkook Pharmaceutical Co., Ltd.Lead sponsor
- Ewha Womans UniversityOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.